GNE-149

GNE-149 is an orally bioavailable full antagonist of estrogen receptor α ( ERα ; IC 50 =0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer In Vitro GNE-149 exhibits antiproliferative activity in MCF7 and T47D cells with IC 50 s of 0.66 and 0.69 nM, respectively. GNE-149 exhibits ERα Degradation in MCF7 and T47D cells with IC 50 s of 0.053 and 0.031 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo GNE-149 (0.3-30 mg/kg) exhibits in vivo efficacy in an MCF7 xenograft mouse model harboring either wild-type (WT) ERα or overexpressed Y537S mutant . GNE-149 has favorable pharmacokinetic profile, including total clearance (CL; 19, 8, and 13 mL/min/kg for Rat, Dog, and Cyno) and oral bioavailability (F; 31%, 49%, and 28% for Rat, Dog, and Cyno) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Crl:NU Foxn1 nu mice (at 7 weeks of age) bearing wild-type (WT) ERαor overexpressed Y537S mutant MCF7 tumor Dosage: 0.3, 1, 3, 10, and 30 mg/kg Administration: Orally q.d. for 21 days Result: Exhibited dose-dependent efficacy in the MCF7 WT and Y537S mutant xenograft model, with tumor regression observed at all doses above 0.3 mg/kg in Y537S mutant xenograft model. Form:Solid IC50& Target:ERα 0.053 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet